Amprenavir
From Wikipedia, the free encyclopedia
| Image:Amprenavir.png | |
| Amprenavir
| |
| Systematic (IUPAC) name | |
| tetrahydrofuran-3-yl [3-[(4-aminophenyl)sulfonyl- (2-methylpropyl) amino] -1-benzyl-2- hydroxy-propyl] aminomethanoate | |
| Identifiers | |
| CAS number | 161814-49-9 |
| ATC code | J05AE05 |
| PubChem | 65016 |
| DrugBank | APRD00605 |
| Chemical data | |
| Formula | C25H35N3O6S |
| Mol. weight | 505.628 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 90% |
| Metabolism | ? |
| Half life | 7.1-10.6 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Amprenavir (Agenerase®) is a protease inhibitor used to treat HIV. It was approved by the Food and Drug Administration on April 15, 1999, for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200mg, delivered in eight very large gel capsules. Production of amprenavir was discontinued by the manufacturer December 31, 2004.
| Antivirals (primarily J05A, also S01AD and D06BB) edit | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||||||||||||

